Breast Cancer Therapeutics Market Size, Share and Industry Analysis By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Cancer Type (Hormone Receptor, HER2+), and Regional Forecast, 2020 - 2029 (Includes COVID-19 Business Impact)

                                          
We have updated Breast Cancer Therapeutics Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the Breast Cancer Therapeutics market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Breast Cancer Therapeutics market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Breast Cancer Therapeutics Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Breast Cancer Therapeutics Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Breast Cancer Therapeutics Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

 	
Genentech (F. Hoffmann-La Roche Ltd)
 	
Eli Lilly and Company
 	
Celgene Corporation
 	
AstraZeneca
 	
Pfizer Inc.
 	
Sanofi
 	
Eisai Co. Ltd.
 	
Kyowa Kirin
 	
Bristol Myers Squibb
 	
Mayne Pharma Group Limited
 	
Novartis AG
 	
Valeant Pharmaceuticals

Report Overview

The increasing prevalence of all classes of cancers are prevalent in the general population and breast cancer comprises of one of the most common forms of cancer. The increasing prevalence and incidence of breast cancer across women and in some instances, men, across all the age groups have led to increased demand for breast cancer therapeutics. According to Breastcancer.org, an estimated 1 in 8 women in the U.S., will develop invasive breast cancer over the individuals lifetime.

The report provides qualitative and quantitative insights on the global breast cancer therapeutics industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market segments include therapy, distribution channel, cancer type, distribution channel, and geography. On the basis of therapy, the market is categorized into therapy (targeted therapy, hormonal therapy, and chemotherapy). Targeted therapy is further sub-segmented into abemaciclib, ado-trastuzumab emtansine, everolimus, trastuzumab, ribociclib, palbociclib, pertuzumab, olaparib, and others.

Hormonal therapy is further sub-segmented into selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor downregulators (ERDs). On the basis of distribution channel, the global industry is categorized into hospital pharmacy, retail pharmacy, online pharmacy, and others, while the market is classified on the basis of cancer type into hormone receptor and HER2+.

Along with this, the report analysis includes breast cancer therapeutics market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of breast cancer therapeutics by key countries, regulatory scenario by key regions, key industry developments and overview of current advances in R&D for breast cancer therapeutics.

SEGMENTATION

By Therapy

 	
Targeted Therap
 	
Abemacicli
 	
Ado-Trastuzumab Emtansine
 	
Everolimus
 	
Trastuzumab
 	
Ribociclib
 	
Palbociclib
 	
Pertuzumab
 	
Olapari
 	
Others
 	
Hormonal Therapy
 	
Selective Estrogen Receptor Modulators (SERMs)
 	
Aromatase Inhibitors
 	
Estrogen Receptor Downregulators (ERDs)
 	
Chemotherapy

By Distribution Channel

 	
Hospital Pharmacies
 	
Retail Pharmacies
 	
Online Pharmacies
 	
Others

By Cancer Type

 	
Hormone Receptor
 	
HER2+

By Geography

 	
North America (U.S. and Canada)
 	
Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
 	
Asia Pacific (China, India, Japan, Australia, South East Asia and Rest of Asia Pacific)
 	
Latin America (Brazil, Mexico and Rest of Latin America
 	
Middle East & Africa (GCC, South Africa and Rest of Middle East & Africa)

Key Industry Developments

In October 2020, Novartis Europharm Limited received marketing authorization valid throughout the European Union for Piqray (active substance alpelisib) which is a cancer medicine used to treat postmenopausal women and men with breast cancer that is locally advanced or has spread to other parts of the body. Piqray can only be used when the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not have large quantities of another receptor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called PIK3CA. Piqray is used with the medicine fulvestrant. The active substance in Piqray, alpelisib, works by blocking the activity of the abnormal PI3K, thereby reducing the growth and spread of the cancer. Piqray used with fulvestrant increased the time before the disease got worse in patients with HR-positive and HER2-negative breast cancer that is advanced or has spread. Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity.

The cost for Piqray oral tablet (200 mg-50 mg) is around USD$17,000 for a supply of 60 tablets. Piqray is available as a brand name drug only, a generic version is not yet available

In July 2020, Accord Healthcare S.L.U. received marketing authorization valid throughout the European Union for Zercepac(trastuzumab). Zercepac can only be used when cancer overexpresses HER2: this means that cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Zercepac has a highly similar structure, purity, and biological activity to Herceptin and is distributed in the body in the same way. In addition, studies in metastatic breast cancer that overexpressed HER2 have shown that the effectiveness of Zercepac infusion is equivalent to that of Herceptin infusion.

The cost for Herceptin intravenous powder in the US for injection of 150 mg is around $1,500 for a supply of 1 powder for injection.

UK trastuzumab market is size is close to US$96.2 Million in 2020.

In April 2020, Shanghai Henlius Biopharmaceutical Co., Ltd. a wholly-owned subsidiary of the Company, received two Certificates of GMP Compliance of a Manufacturer from Poland’s Chief Pharmaceutical Inspector. The Company’s drug substance (DS) line and drug product (DP) line for HLX02 trastuzumab biosimilar at Xuhui District, Shanghai has successfully passed the Good Manufacturing Practice (GMP) on-site inspection by the EU. In May 2020, the MAA of HLX02 submitted by Accord Healthcare S.L.U. has adopted a positive opinion and recommended approval for MAA from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

In May 2019, Novartis announced U.S. FDA approval for the companys new launch of breast cancer therapeutic called Piqray, a PI3K inhibitor for the treatment of advanced breast cancer

In May 2019, Roche announced the U.S. FDA approval of Kadcyla, a breast cancer therapeutic, for the adjuvant treatment of individuals with HER2+ early breast cancer with residual invasive disease after neoadjuvant treatment

In April 2019, Emcure Pharma announced the future launch of the generic version of Eisai Pharmas breast cancer.